ストックスクリーナーアプリを入手
1.0635
5.04%
-0.0565
前日終値:
$1.12
開ける：
$1.1
24時間の取引高:
121
Relative Volume:
0.00
時価総額：
$47.06M
収益：
$18.89M
当期純損益:
$-20.44M
株価収益率:
-1.3501
EPS:
-0.7877
ネットキャッシュフロー:
$-46.69M
1週間 パフォーマンス:
+1.29%
1か月 パフォーマンス:
-7.52%
6か月 パフォーマンス:
+7.19%
1年 パフォーマンス:
-59.10%
1日の値動き範囲:
$1.10
$1.10
1週間の範囲:
$1.04
$1.18
52週間の値動き範囲:
$0.50
$2.99
Elutia Inc Stock (ELUT) Company Profile
Compare ELUT vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
1.10 | 47.92M | 18.89M | -20.44M | -46.69M | -0.7877 |
ABT
Abbott Laboratories
|
104.71 | 182.16B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
326.12 | 125.39B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.45 | 112.84B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.89 | 103.71B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.13 | 48.01B | 6.07B | 1.06B | 1.34B | 1.8063 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-11-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-02 | 開始されました | Cowen | Outperform |
| 2020-11-02 | 開始されました | Piper Sandler | Overweight |
| 2020-11-02 | 開始されました | Truist | Buy |
Elutia Inc (ELUT) 最新ニュース
Earnings Miss: Can Elutia Inc be recession proof2026 Technicals & Verified Momentum Stock Ideas - baoquankhu1.vn
If You Invested $1,000 in Elutia Inc. (ELUT) - Stock Titan
Earnings Beat: Can Elutia Inc generate free cash flow2026 Historical Comparison & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Elutia Inc. (NASDAQ:ELUT) Q4 2025 earnings call transcript - MSN
Elutia (ELUT) Q4 2025 Earnings Call Transcript - AOL.com
Forecast Cut: Is Elutia Inc subject to activist investor interest2026 Earnings Surprises & Low Risk High Reward Ideas - baoquankhu1.vn
Aug Technicals: Is Elutia Inc subject to activist investor interest2026 Price Momentum & Weekly Momentum Stock Picks - baoquankhu1.vn
Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19 - Bitget
Elutia details tech to address infections in breast reconstruction - Stock Titan
Elutia Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Elutia Warns of Ongoing Nasdaq Delisting Risk Despite Recent Compliance Win - TipRanks
Elutia (ELUT) Grants Stock Options to New Hires - GuruFocus
Elutia announces grants of inducement awards - TipRanks
Exit Recap: Is Elutia Inc subject to activist investor interest2026 Market Mood & Detailed Earnings Play Strategies - baoquankhu1.vn
Elutia 2025 10-K: Revenue $12.3M, EPS (cont. ops) $(15.871)M - TradingView
Elutia (NASDAQ: ELUT) pivots to drug‑eluting biomatrix after asset divestitures - Stock Titan
Achieving Micron-Level Tolerances: CAD Optimization for Sub-10µm 3D Printing - AOL.com
Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (RLAY), Stryker (SYK) and Elutia (ELUT) - The Globe and Mail
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Bitget
Elutia markets another product for sale as it pivots to breast reconstruction infection prevention - The Business Journals
Elutia grants 460,000 stock options to 3 new hires at $1.09 - Stock Titan
[Form 4] ELUTIA INC. Insider Trading Activity - Stock Titan
Elutia (ELUT) CEO receives stock from RSU vesting while shares withheld for taxes - Stock Titan
Elutia Q4 2025 slides: $88M sale funds pivot to breast reconstruction - Investing.com Australia
Elutia Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ELUT) 2026-03-12 - Seeking Alpha
Elutia Reports Strong 2025 Financial Results, Advances NXT-41x for Breast Cancer Surgery, and Closes $88M BioEnvelope Sale to Boston Scientific - Minichart
Elutia Inc (ELUT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Moves Amid ... By GuruFocus - Investing.com Canada
Elutia Inc (ELUT) Q4 2025 Earnings Call Highlights: Revenue Grow - GuruFocus
Elutia outlines launch timeline for NXT-41x in $1.5B breast reconstruction market while strengthening leadership team - MSN
Elutia Q4 2025 slides: $88M sale funds pivot to breast reconstruction By Investing.com - Investing.com South Africa
Elutia Inc. (ELUT) Q4 2025 Earnings Call Transcript Summary - 富途牛牛
Elutia Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process - Bitget
Earnings call transcript: Elutia Q4 2025 beats forecasts, stock steady By Investing.com - Investing.com Australia
Earnings call transcript: Elutia Q4 2025 beats forecasts, stock steady - Investing.com
Elutia Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Elutia earnings beat by $1.60, revenue topped estimates - Investing.com Canada
Elutia reports $3.3M Q4 revenue, $70.8M net income on BioEnvelope sale; $44.4M year-end cash - TradingView
ELUTIA ($ELUT) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
Elutia Q4 revenue rises on higher cardiovascular product sales - TradingView
ELUT: Q4 2025 revenue up 16% year-over-year; focus shifts to NXT-41x for breast reconstruction - TradingView
Elutia (NASDAQ: ELUT) posts 2025 profit as BioEnvelope sale cuts debt and funds NXT-41 - Stock Titan
ELUT: Q4 net income soared to $70.8M on BioEnvelope sale, with NXT-41x FDA process underway - TradingView
Elutia Inc. Adopts 2026 Inducement Award Plan and Files Form 8-K Disclosure - Minichart
Exploring Elutia's Earnings Expectations - Benzinga
Elutia Inc (ELUT) Q4 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Elutia Adopts 2026 Inducement Equity Award Plan - TipRanks
ELUT Board adopts 2026 Inducement Award Plan - TradingView
Elutia (NASDAQ: ELUT) sets 2026 inducement plan for 2,000,000 share awards - Stock Titan
Elutia Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Elutia Inc (ELUT) 財務データ
収益
当期純利益
現金流量
EPS
Elutia Inc (ELUT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| NEELS GUIDO J | Director |
Jan 30 '26 |
Buy |
1.04 |
20,000 |
20,800 |
118,750 |
| NEELS GUIDO J | Director |
Jan 29 '26 |
Buy |
1.06 |
15,000 |
15,900 |
98,750 |
| NEELS GUIDO J | Director |
Jan 28 '26 |
Buy |
1.06 |
15,000 |
15,900 |
83,750 |
0.00%
0.00%
大文字化:
|
ボリューム (24 時間):